Browsing ICR Divisions by author "Klampatsa, Astero"
Now showing items 1-8 of 8
-
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.
Klampatsa, A; Leibowitz, MS; Sun, J; Liousia, M; Arguiri, E; et al. (CELL PRESS, 2020-09-25)The therapeutic efficacy of adoptive transfer of T cells transduced with chimeric antigen receptors (CARs) has been limited in the treatment of solid cancers, partly due to tumor antigen heterogeneity. Overcoming lack of ... -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
Hawkins, ER; D'Souza, RR; Klampatsa, A (DOVE MEDICAL PRESS LTD, 2021-01-01)Chimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic receptor which redirects effector function to the tumor, to improve efficacy and reduce toxicities associated with conventional ... -
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
Klampatsa, A; Haas, AR; Moon, EK; Albelda, SM (MDPI, 2017-09-01)Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes ... -
Current Advances in CAR T Cell Therapy for Malignant Mesothelioma.
Klampatsa, A; Albelda, SM (Scientific Archives LLC, 2020-06-22)Malignant mesothelioma is a relatively rare malignancy arising in the body's serosal surfaces, with malignant pleural mesothelioma (MPM) being the most common type. It is characterized by local spread within the thorax, ... -
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa, A; Achkova, DY; Davies, DM; Parente-Pereira, AC; Woodman, N; et al. (ELSEVIER IRELAND LTD, 2017-05-01)Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one ErbB family member was expressed in 88% of tumors. ... -
Mesothelin-targeted CAR-T cell therapy for solid tumors.
Klampatsa, A; Dimou, V; Albelda, SM (TAYLOR & FRANCIS LTD, 2021-04-03)Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged ... -
Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.
Dimou, P; Trivedi, S; Liousia, M; D'Souza, RR; Klampatsa, A (MDPI, 2022-04-06)Precision-cut tumor slices (PCTS) have recently emerged as important ex vivo human tumor models, offering the opportunity to study individual patient responses to targeted immunotherapies, including CAR-T cell therapies. ... -
Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.
Davis, RW; Klampatsa, A; Cramer, GM; Kim, MM; Miller, JM; et al. (AMER ASSOC CANCER RESEARCH, 2023-09-11)UNLABELLED: Surgical cytoreduction for patients with malignant pleural mesothelioma (MPM) is used for selected patients as a part of multi-modality management strategy. Our group has previously described the clinical use ...